Literature DB >> 17581997

Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system.

Zhen Zhang1, Jenny Rowe, Weijia Wang, Marvin Sommer, Ann Arvin, Jennifer Moffat, Hua Zhu.   

Abstract

To efficiently generate varicella-zoster virus (VZV) mutants, we inserted a bacterial artificial chromosome (BAC) vector in the pOka genome. We showed that the recombinant VZV (VZV(BAC)) strain was produced efficiently from the BAC DNA and behaved indistinguishably from wild-type virus. Moreover, VZV's cell-associated nature makes characterizing VZV mutant growth kinetics difficult, especially when attempts are made to monitor viral replication in vivo. To overcome this problem, we then created a VZV strain carrying the luciferase gene (VZV(Luc)). This virus grew like the wild-type virus, and the resulting luciferase activity could be quantified both in vitro and in vivo. Using PCR-based mutagenesis, open reading frames (ORF) 0 to 4 were individually deleted from VZV(Luc) genomes. The deletion mutant viruses appeared after transfection into MeWo cells, except for ORF4, which was essential. Growth curve analysis using MeWo cells and SCID-hu mice indicated that ORF1, ORF2, and ORF3 were dispensable for VZV replication both in vitro and in vivo. Interestingly, the ORF0 deletion virus showed severely retarded growth both in vitro and in vivo. The growth defects of the ORF0 and ORF4 mutants could be fully rescued by introducing wild-type copies of these genes back into their native genome loci. This work has validated and justified the use of the novel luciferase VZV BAC system to efficiently generate recombinant VZV variants and ease subsequent viral growth kinetic analysis both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581997      PMCID: PMC1951468          DOI: 10.1128/JVI.02666-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model.

Authors:  Takahiro Niizuma; Leigh Zerboni; Marvin H Sommer; Hideki Ito; Stewart Hinchliffe; Ann M Arvin
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 2.  In vivo bioluminescence imaging for integrated studies of infection.

Authors:  Timothy C Doyle; Stacy M Burns; Christopher H Contag
Journal:  Cell Microbiol       Date:  2004-04       Impact factor: 3.715

3.  Live vaccine used to prevent the spread of varicella in children in hospital.

Authors:  M Takahashi; T Otsuka; Y Okuno; Y Asano; T Yazaki
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse.

Authors:  Jaya Besser; Marvin H Sommer; Leigh Zerboni; Christoph P Bagowski; Hideki Ito; Jennifer Moffat; Chia-Chi Ku; Ann M Arvin
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Coupling generation of cytomegalovirus deletion mutants and amplification of viral BAC clones.

Authors:  Weijia Wang; Catherine E Patterson; Shaojun Yang; Hua Zhu
Journal:  J Virol Methods       Date:  2004-11       Impact factor: 2.014

6.  Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro.

Authors:  J I Cohen; K E Seidel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

7.  Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts.

Authors:  Kimiyasu Shiraki; Yoshihiro Yoshida; Yoshizo Asano; Koichi Yamanishi; Michiaki Takahashi
Journal:  J Infect Dis       Date:  2003-12-08       Impact factor: 5.226

8.  Varicella-zoster virus open reading frame 1 encodes a membrane protein that is dispensable for growth of VZV in vitro.

Authors:  J I Cohen; K E Seidel
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

9.  The UL55 and UL56 genes of herpes simplex virus type 1 are not required for viral replication, intraperitoneal virulence, or establishment of latency in mice.

Authors:  T C Nash; J G Spivack
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

10.  Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli.

Authors:  Kazuhiro Nagaike; Yasuko Mori; Yasuyuki Gomi; Hironori Yoshii; Michiaki Takahashi; Markus Wagner; Ulrich Koszinowski; Koichi Yamanishi
Journal:  Vaccine       Date:  2004-09-28       Impact factor: 3.641

View more
  48 in total

1.  Herpesvirus systematics.

Authors:  Andrew J Davison
Journal:  Vet Microbiol       Date:  2010-02-11       Impact factor: 3.293

Review 2.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

3.  Varicella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3.

Authors:  Huifang Zhu; Chunfu Zheng; Junji Xing; Shuai Wang; Shuping Li; Rongtuan Lin; Karen L Mossman
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Interaction of allergy history and antibodies to specific varicella-zoster virus proteins on glioma risk.

Authors:  Seung-Tae Lee; Paige Bracci; Mi Zhou; Terri Rice; John Wiencke; Margaret Wrensch; Joseph Wiemels
Journal:  Int J Cancer       Date:  2013-10-31       Impact factor: 7.396

Review 5.  Recent advances in cloning herpesviral genomes as infectious bacterial artificial chromosomes.

Authors:  Fuchun Zhou; Shou-Jiang Gao
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

6.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

7.  Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors.

Authors:  Mohamed I Khalil; Marvin Sommer; Ann Arvin; John Hay; William T Ruyechan
Journal:  Virology       Date:  2013-03-21       Impact factor: 3.616

8.  Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor.

Authors:  Zhen Zhang; Anca Selariu; Charles Warden; Grace Huang; Ying Huang; Oluleke Zaccheus; Tong Cheng; Ningshao Xia; Hua Zhu
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

9.  Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts.

Authors:  Stefan L Oliver; Leigh Zerboni; Marvin Sommer; Jaya Rajamani; Ann M Arvin
Journal:  J Virol Methods       Date:  2008-09-24       Impact factor: 2.014

10.  Varicella-zoster virus IE4 protein interacts with SR proteins and exports mRNAs through the TAP/NXF1 pathway.

Authors:  Isabelle Ote; Marielle Lebrun; Patricia Vandevenne; Sébastien Bontems; Cahora Medina-Palazon; Evelyne Manet; Jacques Piette; Catherine Sadzot-Delvaux
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.